20 articles
Amgen expands late-stage testing of its long-acting obesity drug MariTide, including a trial for patients switching from rival GLP-1 medications.
Peter Attia dissects the null results of the MET-PREVENT trial and what they reveal about the hard science of testing aging interventions.
ATX-304 raised resting metabolic rate 8%, slashed triglycerides, and reduced liver fat in an 8-week Phase 1b trial for prediabetes.
Cambrian Bio's ATX-304 reduced liver fat, visceral fat, and raised resting metabolic rate by 8% in a Phase 1b trial of adults with prediabetes.
A landmark 21-year trial finds diet and exercise interventions cut multimorbidity risk by 21% in prediabetic adults โ metformin showed no such benefit.
Phase III trials show once-weekly CagriSema outperforms placebo on HbA1c and body weight in multiple type 2 diabetes populations.
The ACHIEVE-5 trial shows orforglipron added to basal insulin significantly lowered HbA1c and reduced body weight without raising hypoglycemia risk.
Breakthrough research reveals metformin works through the brain, not just the liver, opening new doors for diabetes treatment.
AstraZeneca's oral GLP-1 drug elecoglipron showed meaningful weight loss and blood sugar reduction in two mid-stage trials published in the Lancet.
Phase II trial shows petrelintide, a weekly amylin injectable, achieves meaningful weight loss with far fewer nausea and vomiting events than GLP-1 drugs.
A novel ฮฒ2 agonist pill boosts fat burning via skeletal muscle, preserving muscle mass while improving blood sugar in early trials.
A major RCT shows finerenone reduces kidney function loss by 23% in non-diabetic CKD patients, expanding its protective role beyond diabetes.
New data from 111,000+ women shows GLP-1 agonists cut breast cancer rates by 30%, spurring a major prevention trial.
A new study links GLP-1 agonists to dramatic survival benefits in breast cancer patients, but experts warn the results are likely too good to be true.
Retatrutide achieves surgical-level weight loss in 80 weeks, plus key updates on T1D screening, GLP-1 risks, and teen diabetes rates.
Cambrian Bio's ATX-304 combines AMPK and mitochondrial activation in a pill form, with Phase 1b data in prediabetic obese adults due this week.
Tirzepatide outperforms semaglutide on weight loss but may strip more muscle. Plus: fructose, keto diets, and cardiac benefits of oral GLP-1s.
OrsoBio's mitochondrial drug TLC-6740 added 4.5% more weight loss on top of tirzepatide in a Phase 2a trial, with bonus metabolic and cognitive benefits.
MetaVia's dual-action GLP-1/glucagon receptor drug DA-1726 shows rapid, sustained weight loss in Phase 1 trials with a strong safety profile.
Two popular longevity drugs show evidence of interfering with the body's response to exercise โ a critical tradeoff for active users.
